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L E T T E R TO TH E ED I TOR
Lack of evidence for the use of ustekinumab for acute severe
ulcerative colitis
Dear Editor,
We read with interest clinical outcomes with ustekinumab as
rescue treatment in therapy‐refractory or therapy‐intolerant ulcer-
ative colitis (UC),1 which aimed to assess the use of ustekinumab as
rescue therapy for severe colitis. This retrospective analysis of 19
patients reported clinical remission of 53% at 1 year following
ustekinumab therapy.
Our concern with this study is it defines acute severe ulcerative
colitis (ASUC) using the colitis activity index (CAI) with a median
score of 8.5, which would indicate either very mild or, at the very
worse, moderate disease and hence this cannot be defined as acute
severe colitis. Significantly, this score has yet to be validated as a tool
to accurately define severe colitis and hence other validated scores
would have provided more accuracy to the severity of the UC. We
also note that inclusion to the study was for those patients who had
not induced adequate clinical response. The baseline data however
state that at least six of the patients in this study had CAI scores of 6
or less; clearly far from scores that would imply acute severe UC.
Three of the patients that were included in this study were in
remission and hence would not be considered ASUC. Moreover, it is
difficult to appreciate why patients in, or approaching, clinical
remission were commenced on ustekinumab.
A further significant point is reference to remission in acute
colitis. In the Unifi studies, remission is defined at Week 8 in the
induction phase and at Week 44 in the maintenance phase of the
study.2 It is, therefore, difficult to compare outcomes with the UNIFI
study when outcomes at 8 weeks were not available. Furthermore,
much stricter criteria were used in the UNIFI study to define mod-
erate‐to‐severe colitis and hence we feel the results are not com-
parable. One final concern is the definition of remission, with 1 of the
10 who achieved remission still requiring steroids at the end of
12 months. Usually, steroid‐free remission is the gold standard used
to define remission in most studies.
We believe this study highlights that ustekinumab may be a
useful second‐ or third‐line therapy for mild‐to‐moderate UC to help
maintain remission, but feel that this manuscript does not demon-
strate that ustekinumab can be used as rescue treatment for ASUC.
Crucially, given that the study title and aims could potentially lead to
unsafe/unproven treatment strategies for patients with ASUC, we
would recommend that the journal considers publishing a corri-
gendum for clarification.
Jonathan P. Segal1 , Mohammed Nabil Quraishi2,3
1Department of Gastroenterology, The Hillingdon Hospital,
Uxbridge, UK
2University of Birmingham Microbiome Treatment Centre,
University of Birmingham, Birmingham, UK
3Department of Gastroenterology, Queen Elizabeth Hospital
Birmingham, University Hospitals Birmingham NHS Foundation
Trust, Birmingham, UK
Correspondence
Jonathan P. Segal, The Hillingdon Hospital,
Uxbridge UB8 3NN, UK.
Email: jonathansegal1@nhs.net
ORCID
Jonathan P. Segal https://orcid.org/0000-0002-9668-0316
REFERENCES
1. Ochsenkühn T, Tillack C, Szokodi D, et al. Clinical outcomes with
ustekinumab as rescue treatment in therapy‐ refractory or therapy‐
intolerant ulcerative colitis. United Eur Gastroenterol J. 2020;8:91–8.
2. Sands BE, Sandborn WJ, Panaccione R, et al. Ustekinumab as in-
duction and maintenance therapy for ulcerative colitis. N Engl J Med.
2019;381:1201–14.
© 2020 The Authors. UEG Journal published by John Wiley & Sons LLC.
United European Gastroenterol J. 2021;9:127. wileyonlinelibrary.com/journal/ueg2 - 127
